Published time: August 28, 2014 22:53
Edited time: August 29, 2014 07:03
Twenty healthy volunteers will next week enter a 48-week trial for a US-developed vaccine against the deadly Ebola virus. The trial has been moved forward due to the current outbreak, but the first results are unlikely before the year end.
The vaccine, which is aimed against two of the most common strains of Ebola, should replicate animal studies, in which it stimulated an immune response, producing antibodies, but not infecting the patient. Similar tests of the medicine, co-developed by pharmaceuticals megalith GlaxoSmithKline (GSK), may begin on UK volunteers next month.
“I have been fooled enough in my many years of experience in infectious disease vaccinology that you really can’t predict what you might see,” said Anthony Fauci, the director of the state-run National Institute of Allergy and Infectious Diseases (NIAID), which will be conducting…
View original post 433 woorden meer